로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > BTLA

BTLA

요약

Name:B- and T-lymphocyte attenuator
Target Synonym:BTLA,B- and T-lymphocyte attenuator,B- and T-lymphocyte-associated protein,B And T Lymphocyte Associated,CD272 Antigen,BTLA1,CD272
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 3 Clinical

제품 리스트 구매

일부의 생물활성 데이터

SCJUR-STF106-Cell-based assay
 BTLA FACS

Expression analysis of human BTLA on Human BTLA (Luc) Jurkat Reporter Cell by FACS.
Human BTLA (Luc) Jurkat Reporter Cell or negative control cell were stained with PE-labeled anti-human BTLA antibody.

SCCHO-ATP110-Cell-based assay
 BTLA FACS

Expression analysis of human BTLA on CHO/Human BTLA Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human BTLA Stable Cell Line or negative control cell using PE-labeled anti human BTLA antibody.

BTA-H52H3-BLI
 BTLA BLI

Loaded Human BTLA (31-150), His Tag (Cat. No. BTA-H52H3) on NTA Biosensor, can Human HVEM, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. HVM-H5255) with an affinity constant of 20.8 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

BTA-H82E4-ELISA
 BTLA ELISA

Immobilized Biotinylated Human BTLA (31-150), His,Avitag (Cat. No. BTA-H82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human HVEM, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. HVM-H5255) with a linear range of 2-78 ng/mL (QC tested).

Synonym Name

BTLA,CD272

Background

B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

Clinical and Translational Updates

Related Molecule

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
HFB-200603 HFB-200603 Phase 1 Clinical HiFiBiO Therapeutics Carcinoma, Renal Cell; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Tifcemalimab TAB-004; JS-004 Phase 3 Clinical Shanghai Junshi Biosciences Co Ltd Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Hodgkin Disease; Nasopharyngeal Carcinoma; Lymphoma; Lung Neoplasms; Melanoma; Neoplasm Metastasis Details
ANB-032 ANB-032 Phase 2 Clinical Anaptysbio Inc Inflammation; Dermatitis, Atopic; Eczema Details
Venanprubart LY-3361237 Phase 2 Clinical Sanford-Burnham Medical Research Institute, Eli Lilly And Company Sjogren's Syndrome; Lupus Erythematosus, Systemic; Psoriasis Details
MB-272 MB272; GS-0272 Phase 1 Clinical University Of Oxford, MiroBio Ltd Arthritis, Rheumatoid; Autoimmune Diseases; Lupus Erythematosus, Systemic Details

This web search service is supported by Google Inc.

totop